CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2026)
CRISPR Therapeutics AG (CRSP) posted Operating Leases of $183.6 million for Q1 2026, down 2.45% sequentially from $188.2 million in Q4 2025, and down 9.06% YoY from $201.9 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Operating Leases for 8 years, with the latest figure at $183.6 million in Q1 2026.
- Quarterly Operating Leases fell 9.06% year-over-year to $183.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183.6 million (down 9.06% YoY) and the FY2025 annual result came in at $188.2 million, down 8.84% from the prior year.
- Operating Leases slipped to $183.6 million in Q1 2026 per CRSP's latest filing, from $188.2 million in the prior quarter.
- Over five years, Operating Leases peaked at $234.2 million in Q2 2022 and troughed at $183.6 million in Q1 2026.
- A 5-year average of $214.1 million and a median of $218.9 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2026: Operating Leases soared 361.27% in 2022, then retreated 9.06% in 2026.
- Over 5 years, Operating Leases stood at $228.2 million in 2022, then fell by 2.27% to $223.0 million in 2023, then fell by 7.44% to $206.4 million in 2024, then retreated by 8.84% to $188.2 million in 2025, then declined by 2.45% to $183.6 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $183.6 million, $188.2 million, and $192.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 178.90 Mn |
| Mar 31, 2026 | 183.56 Mn |
| Dec 31, 2025 | 188.17 Mn |
| Sep 30, 2025 | 192.77 Mn |
| Jun 30, 2025 | 197.43 Mn |
| Mar 31, 2025 | 201.85 Mn |
| Dec 31, 2024 | 206.41 Mn |
| Sep 30, 2024 | 210.66 Mn |
| Jun 30, 2024 | 214.85 Mn |
| Mar 31, 2024 | 218.94 Mn |
| Dec 31, 2023 | 223.01 Mn |
| Sep 30, 2023 | 226.59 Mn |
| Jun 30, 2023 | 230.34 Mn |
| Mar 31, 2023 | 224.55 Mn |
| Dec 31, 2022 | 228.18 Mn |
| Sep 30, 2022 | 230.90 Mn |
| Jun 30, 2022 | 234.16 Mn |
| Mar 31, 2022 | 227.90 Mn |
| Dec 31, 2021 | 212.87 Mn |
| Sep 30, 2021 | 192.73 Mn |